Penumbra Inc (NYSE:PEN) insider Daniel Donen Davis sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $88.80, for a total transaction of $2,664,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Penumbra Inc (NYSE:PEN) traded up $0.65 during midday trading on Friday, hitting $90.10. 299,800 shares of the company were exchanged, compared to its average volume of 403,350. Penumbra Inc has a twelve month low of $67.95 and a twelve month high of $116.35. The company has a market cap of $3,060.00 and a P/E ratio of 429.05.

Penumbra (NYSE:PEN) last released its earnings results on Tuesday, November 7th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.07. Penumbra had a negative net margin of 2.19% and a negative return on equity of 1.95%. The business had revenue of $83.90 million for the quarter, compared to the consensus estimate of $79.17 million. During the same period in the previous year, the firm earned ($0.04) EPS. The business’s revenue for the quarter was up 24.9% on a year-over-year basis. sell-side analysts predict that Penumbra Inc will post -0.15 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. raised its holdings in shares of Penumbra by 7.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 121,352 shares of the company’s stock valued at $10,649,000 after acquiring an additional 8,749 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Penumbra by 0.8% during the second quarter. Bank of New York Mellon Corp now owns 149,083 shares of the company’s stock valued at $13,082,000 after acquiring an additional 1,234 shares during the period. Legal & General Group Plc raised its holdings in shares of Penumbra by 13.6% during the second quarter. Legal & General Group Plc now owns 10,164 shares of the company’s stock valued at $888,000 after acquiring an additional 1,218 shares during the period. Prudential Financial Inc. acquired a new stake in shares of Penumbra during the second quarter valued at approximately $252,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Penumbra by 10.9% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,159 shares of the company’s stock valued at $102,000 after acquiring an additional 114 shares during the period. Institutional investors and hedge funds own 71.71% of the company’s stock.

A number of analysts recently commented on the stock. BMO Capital Markets reiterated a “buy” rating and issued a $96.00 target price on shares of Penumbra in a report on Friday, October 13th. Canaccord Genuity boosted their target price on shares of Penumbra from $100.00 to $113.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th. Zacks Investment Research downgraded shares of Penumbra from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. Finally, JPMorgan Chase & Co. downgraded shares of Penumbra from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 2nd. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $111.50.

COPYRIGHT VIOLATION NOTICE: “Penumbra Inc (PEN) Insider Daniel Donen Davis Sells 30,000 Shares” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2018/01/19/penumbra-inc-pen-insider-daniel-donen-davis-sells-30000-shares.html.

Penumbra Company Profile

Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.